Rapid Development and Initial Preclinical Evaluation of an Effective Candidate Vaccine against SARS-CoV-2
The current pandemic caused by SARS-CoV-2 is a threat not only to global health but also to the economy since it is dramatically affecting the socioeconomic layers of societies around the planet. Thus, it will be critically important to advance in the production of an effective vaccine, which will be crucial for building up sufficient population-based immunity to efficiently curb the pandemic. While SARS-CoV-2 can infect everyone at all ages, it is mainly the elderly population that is most at risk of a fatal outcome. Elderly persons are charecterized by a declining immune function, known a...
To date, there is no vaccine and no specific antiviral agent against SARS-CoV-2. Because of hospital saturation, controversial drug efficiency and the risk of medicinal shortage, there is an urgent need for alternative treatment options. Passive (plasmapheresis) and active immunization (vaccine) approaches aim to provide or elicit a protective humoral immune response against SARS-CoV-2. This project aims to develop a high throughput assay to measure the neutralizing activity of COVID-19 patients. It will help characterize the antibody response against SARS-CoV-2, and select the sera with hi...